Features and properties of abrocitinib

Alternative names	Cibinqo®; PF 04965842; PF-4965842
Class	Amines; anti-inflammatories; antipsoriatics; cyclobutanes; pyrimidines; pyrroles; skin disorder therapies; small molecules; sulfonamides
Mechanism of action	JAK1 inhibitor
Route of administration	Oral
Pharmacodynamics	Selective for JAK1 over other JAKs; dose-dependently reduces markers of inflammation; reduces platelet counts and increases LDL-C, HDL-C and total cholesterol levels, in a dose-related fashion
Pharmacokinetics	Rapidly absorbed after oral administration, reaching Cmax within 1 h; elimination half-life ≈ 5 h
Most frequent adverse reactions	Nausea, headache, acne, herpes simplex, blood creatine phosphokinase increased > 5 × upper limit of normal, vomiting, dizziness, upper abdominal pain, herpes zoster
ATC codes
WHO ATC code	D11A-H08 (abrocitinib)
EphMRA ATC code	D11A (other dermatological preparations)
Chemical name	N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide

C_max maximum plasma concentration, HDL-C high-density lipoprotein cholesterol, JAK Janus kinase, LDL-C low-density lipoprotein cholesterol